Antiresorptive therapies and their effects on bone;Die wirkung der antiresorptiven therapie am knochen

Osteologie

Volumn 21, Issue 2, 2012, Pages 63-69

  Bock, Oliver ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiresorptive therapy; Bisphosphonates; Denosumab; Osteoclasts

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; FARNESYL TRANS TRANSFERASE; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

BONE ATROPHY; CELL DIFFERENTIATION; CELL FUNCTION; CORTICAL BONE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FRACTURE; HUMAN; JAW OSTEONECROSIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRENYLATION; REVIEW; TRABECULAR BONE;

EID: 84863003942     PISSN: 10191291     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1621668     Document Type: Review

References (34)

1. Dachverband Osteologie e. V. (DVO). DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Langfassung. Stuttgart, New York: Schattauer 2009.
2. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011; 48 (4): 677-692.
3. Elford PR, Felix R, Cecchini M et al. Murine osteo blastlike cells and the osteogenic cell MC3T3-E1 release a macrophage colony-stimulating activity in culture. Calcif Tissue Int 1987; 41 (3): 151-156.
4. Yoshida H, Hayashi S, Kunisada T et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345 (6274): 442-444. (Pubitemid 120014957)
5. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93 (2): 165-176. (Pubitemid 28180851)
6. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397 (6717): 315-323.
7. Theoleyre S, Wittrant Y, Tat SK et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004; 15 (6): 457-475. (Pubitemid 39550455)
8. Wright HL, McCarthy HS, Middleton J, Marshall MJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009; 2 (1): 56-64.
9. Pederson L, Ruan M, Westendorf JJ et al. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1- phosphate. Proc Natl Acad Sci USA 2008; 105 (52): 20764-20769.
10. Zhao C, Irie N, Takada Y et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4 (2): 111-121. (Pubitemid 44138718)
11. Sims NA. EPHs and ephrins: many pathways to regulate osteoblasts and osteoclasts. IBMS Bone-KEy 2010; 7: 304-313.
12. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49 (1): 2-19.
13. Ebetino FH, Hogan AM, Sun S et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011; 49 (1): 20-33.
14. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19 (6): 733-759.
15. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007; 9 (Suppl 1): S7.
16. Ominsky MS, Kostenuik PJ, Cranmer P et al. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 2007; 18 (8): 1073-1082. (Pubitemid 47020009)
17. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003; 97 (Suppl 3): 802-812. (Pubitemid 36125816)
18. Kostenuik PJ, Nguyen HQ, McCabe J et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24 (2): 182-195.
19. Emery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273 (23): 14363-14367. (Pubitemid 28319153)
20. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11 (1-2): 81-88. (Pubitemid 43227856)
21. Pierroz DD, Bonnet N, Baldock PA et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010; 285 (36): 28164-28173.
22. Tat SK, Padrines M, Theoleyre S et al. OPG/membranous - RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 2006; 39 (4): 706-715. (Pubitemid 44311705)
23. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9 (32): 2643-2658. (Pubitemid 37456015)
24. Gasser JA, Ingold P, Venturiere A et al. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008; 23 (4): 544-551. (Pubitemid 351501895)
25. Ominsky MS, Stolina M, Li X et al. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res 2009; 24 (7): 1234-1246.
26. Li X, Ominsky MS, Stolina M et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 2009; 45 (4): 669-676.
27. Follet H, Li J, Phipps RJ et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007; 40 (4): 1172-1177. (Pubitemid 46386562)
28. Fuchs RK, Shea M, Durski SL et al. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 2007; 41 (2): 290-296. (Pubitemid 47001818)
29. Lespessailles E, Jaffré C, Beaupied H et al. Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats? Calcif Tissue Int 2009; 85 (2): 146-157.
30. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19 (7): 1059-1066. (Pubitemid 41110556)
31. Seeman E, Libanati C, Austin M et al. The Transitory Increase in PTH Following Denosumab Administration is Associated With Reduced Intracortical Porosity: a Distinctive Attribute of Denosumab Therapy. J Bone Miner Res 2011; 26 (Suppl 1): S22.
32. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004; 20 (8): 1291-1300. (Pubitemid 39120794)
33. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011; 22 (12): 2951-2961.
34. th edition. New York: McGraw-Hill Professional 2004.